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Abstract 
Growth hormone (GH) deficiency (GHD) is a rare condition with a prevalence of approximately 1 in 4000 
during childhood. GHD may be either congenital or acquired. The diagnosis of GHD can be difficult, 
particularly in idiopathic isolated GHD. There are significant controversies in the diagnosis of GHD in 
childhood. GH stimulation tests are the key factors in GHD diagnosis, but these tests are poorly 
reproducible and serum GH concentration measurements can vary significantly according to stimulation 
tests and GH assays. Close to GH stimulation tests, other biochemical marker, such as IGF-I are useful, 
together with neuroimaging and genetic tests. These clinical, biochemical and radiological diagnostic 
tools, including their limits, are discussed in this review. 
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Introduction 
Growth hormone deficiency (GHD) is a rare condition with a prevalence of approximately 1 in 
4000 during childhood (1). However, it is important to make an appropriate and correct diagnosis, 
as treatment with recombinant human growth hormone (GH) is very effective in improving final 
height in GHD patients. Conversely, a non-correct diagnosis will lead to unnecessary daily 
injections, exposure to potential adverse effects and unnecessary costs.  
GHD may be either congenital or acquired (Table 1). Congenital causes include genetic mutations 
(either specific to GH secretion such as GHRHR and GH1 genes, or interfering with pituitary 
development and multiple pituitary hormone secretion) and structural brain malformations 
(holoprosencephaly, septo-optic dysplasia, agenesis of corpus callosum, Rathke's cyst). Acquired 
causes include midline tumors (craniopharyngioma, optic nerve glioma, germinoma, and pituitary 
adenoma), cranial irradiation, traumatic brain injury, central nervous system infections and 
inflammatory conditions (sarcoidosis, Langerhan's cell histiocytosis). The diagnosis of GHD can 
be difficult, particularly in idiopathic isolated GHD (iGHD), i.e. where there is no evidence of 
multiple pituitary hormone deficiency (MPHD) or visible cranial abnormalities. The efficacy of 
tools used to diagnose GHD have been widely discussed over the years, due to the lack of a gold 
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standard diagnostic test. The clinical care pathway that leads to diagnosis includes an assessment 
of the patient’s auxology, a biochemical assessment of the GH-IGF-I axis, and imaging of the 
hypothalamo-pituitary axis. 
Consensus guidelines on the diagnosis of GHD in childhood were published in 2000 by the GH 
Research Society (2) and the Clinical Care Pathway for GHD of the Italian Society for Pediatric 
Endocrinology and Diabetes that recently became available on the website (3). 
This article reviews the clinical, biochemical and radiological diagnostic tools, including their 
limits. 
 
Diagnosis of GHD 
In the neonatal period, a random GH measurement of <7 mg/L permits to make a diagnosis of 
GHD. Outside this period, a single random measurement of serum GH concentrations is of no 
clinical value as GH secretion is pulsatile with the majority of GH pulses occurring overnight, 
with very low GH concentrations between pulses. For this reason, provocative tests of GH 
secretion using physiological/pharmacological stimuli are required to definitely assess GHD 
diagnosis. GH stimulation tests are based on a priori defined cut-off concentration for GH peak, 
which allows to distinguish GHD subjects from those who are GH-sufficient. 
The lack of a ‘gold standard’ test for GHD diagnosis has led to the development of arbitrary cut-
off levels. Attempts have been made to optimize the cut-off concentration using auxological 
criteria to define GHD (predominantly height velocity) but these attempts have been hampered, as 
other disorders can share similar auxology to GHD. 
 
 
Table 1. Etiological classification of Growth Hormone Deficiency (GHD). 
Isolated GHD (IGHD) Genetic 
 GH1 Mutations (GHD type 1A) 
 GHRH Mutations (GHD type 1B) 
 GH1 Mutations (GHD type II with evolving pituitary deficiencies) 
 GHD type III (XL Agammaglobulinemia) 
 GH1 Kowarski Syndrome (Bioinactive GH) 
 GHS Mutation/Variant 
 Alstrom Syndrome 
 
Multiple Pituitary Hormone 
Deficiency (MPHD) 
Genetic (Transcription factor defect, gene mutation, deletion or duplication) 
 Genes implicated in early development of hypothalamicepituitary region 
 Genes implicated in early development of brain and hypothalamicepituitary region 
- Holoprosencephaly 
- Septo-optic dysplasia and its spectrum involving eyes 
- Midline defects (cleft-palate, persistence of craniopharyngeal canal, dental 
agenesis, …) 
- Extra brain malformations (ARNT2, CHD7, IGSF1, …) 
- Overlapping Kallmann syndrome (FGF8, FGFR1, PROKR2, PROK2 
CDH7,WDR11, …) 
- Other conditions 
 Genes implicated in cellular differentiation 
Inducing tumor genes (SOX2, BRAF, 
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MPHD Congenital 
 Midline brain and pituitary developmental defects 
 Pituitary aplasia; ectopic posterior pituitary, anterior pituitary hypoplasia and 
pituitary stalk 
 abnormalities (agenesis, hypoplasia); empty sella 
 Congenital CNS mass (hamartoblastoma, hamartoma), cyst. encephalocele 
 
IGHD/MPHD  Idiopathicpermanent 
 Idiopathictransitory 
IGHD/MPHD  Acquired 
 CNS tumors (craniopharyngioma, germinoma, ependymoma, pituitary adenoma, 
meningioma, 
 medulloblastoma, glioma, metastatic tumors (rare), Rathke's cleft cyst, arachnoid 
cyst) 
 Radiotherapy (cranial irradiation for CNS tumors, other malignancies,BMT) 
 TBI (accidental, after neurosurgery, subarachnoid hemorrhage) 
 Infections (meningitis, encephalitis, tuberculosis, hypophysitis) 
 Autoimmune (hypophysitis, APS, anti Pit1antibodies) 
 Infiltration (LCH, hemochromatosis, chronic blood transfusions) 
 Chemotherapy (cancer survivors) 
 GHD, growth hormone deficiency; CPHD, combined pituitary hormone deficiency; 
MPHD, multiple pituitary hormone deficiency; 
 CNS, central nervous system; BMT, bone marrow transplantation; TBI, traumatic 
brain injury; APS, autoimmune polyglandular 
 syndrome; LCH, Langherans cell histiocytosis. 
 
 
When GH stimulation tests were first used in the 1960s, a peak GH concentration after 
stimulation <5 mg/L was considered mandatory for GHD diagnosis 
GH stimulation tests (4). During the subsequent years, this cut-off was increased. In Italy, a GH 
cut-off of 10 mg/L was adopted for a long time, but after 2014 this cut-off has been reduced to 8 
mg/L. Recent studies by Wagner et al have suggested a GH peak cut-off of 7 mg/L (5). 
The first pharmacological test used to diagnose GHD was the insulin tolerance test. Afterwards 
several others pharmacological stimuli were identified, including arginine, clonidine, glucagon, 
levodopa, pyridostigmine, GH releasing hormone (GHRH) and GHRH combined with arginine.  
Most of the pharmacological tests are associated with side effects such as nausea, hypotension 
and somnolence. Very rarely, the insulin tolerance test has been associated with death due to 
hypoglycemia or its overtreatment with high concentrations of dextrose (6).  
Ghigo et al (7) have conducted a study comparing 10 different GH stimulation tests in 472 
children without GHD. Mean GH peak concentrations varied between tests from 9.7 mg/L to 61.8 
mg/L. Excluding combined stimulation tests, all the tests incorrectly classified some subjects as 
GH deficient. Using a cut-off of 7 mg/L, false positive rates varied between 8.9% and 23.7%, 
depending on the test used, and increased to 14.9–49% when the cut-off was increased to 10 
mg/L. Variability in GH peak concentration also occurs between tests when used to investigate 
children with short stature (8). In addition to variability between the GH stimulation tests, the 
reproducibility of stimulation tests is poor (9).  
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Current Italian regulations of GH prescription settled by Italian Medicine Agency (AIFA) 
recommend the use of two pharmacological tests for the diagnosis of GHD, with both tests with a 
response of less than 8 mg/L. This strategy is used to improve diagnostic accuracy given the large 
number of false positive results from single stimulation tests in normal children. 
 
Priming for GH stimulation tests 
During puberty, the activation of the hypothalamo-pituitary-gonadal axis leads to a large increase 
in the circulating concentration of sex steroids with consequent increase of the pulse amplitude of 
GH secretion, IGF-I concentrations and anterior pituitary size. Children in the peripubertal period 
and those with delayed puberty often exhibit a growth velocity deceleration and short stature 
requiring an endocrine assessment. GH testing in this group frequently shows subnormal results. 
However, these patients often normalize their GH secretion during follow-up as demonstrated by 
a reassessment of GH secretion during puberty (10). These data led to the suggestion that the 
primary disfunction in these patients was sex steroid deficiency, with a probable diagnosis of 
constitutional delay. The use of estrogen or testosterone to prime the GH axis prior to 
pharmacological stimulation tests has been demonstrated to increase GH peak concentrations and 
reduce false positive rates in healthy prepubertal subjects from 39% to 5% (11). There is evidence 
from one follow-up study of 50 patients that not treating children with subnormal unprimed GH 
stimulation tests but normal primed GH stimulation tests does not result in an impaired final 
height (12). 
There are three strategies applied to priming by pediatric endocrinologists: a) no priming, b) sex 
steroid priming for children with pubertal delay (prepubertal at 13–14 years in boys and 11–12 years 
in girls), c) Sex steroid priming for all prepubertal children (boys >9 years, girls >8 years, this can be 
based either on chronological age or bone age). Internationally around a third to half of pediatric 
endocrinologists routinely prime peripubertal children prior to GH stimulation testing. 
Common protocols for priming include intramuscular injection of testosterone (100 mg intramuscular, 
7–10 days) before testing for boys and the administration of oral estrogen (eg, 10–20 mg 
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ethinylestradiol) for 48–72 h prior to testing in girls.  
Obesity 
Italian prevalence data indicate that 9% of children aged 6-10 years are classified as obese and 
21% as overweight. Extensive data in the adult population indicated that spontaneous and 
stimulated GH secretion is reduced in obesity and has led to the development of different cut-off 
levels for the diagnosis of GHD in obese or overweight adults (13). Likewise it is clear in 
childhood that obesity is linked to reduced spontaneous GH secretion (14), reduced peak GH 
concentrations to stimulation testing and increased rates of diagnosis of GHD compared with lean 
subjects of similar stature and IGF-I concentrations (15). 
A proportion of this increase in GHD diagnosis in obese subjects is likely to be the result of false 
positive tests due to their obesity, and there is therefore a need for BMI specific cut-off levels for 
peak GH concentrations during pharmacological stimulation testing in childhood and puberty. 
Measurement of IGF-I and IGFBP-3 
Serum IGF-I is mainly derived from the liver under the control of GH and circulates bound to the 
IGF binding proteins (IGFBPs). There are six classical IGFBPs of which IGFBP-3 is the major 
serum carrier of IGF-I. Unlike GH, serum concentrations of IGF-I and IGFBP-3 are stable 
throughout the day. 
Serum IGF-I concentrations vary with age and, unfortunately, the normal range for serum IGF-I 
concentrations in young children overlaps with the range found in children with GHD. 
Additionally, IGF-I concentrations are reduced in children with poor nutrition, hypothyroidism, 
chronic disease, renal failure and diabetes. They also rise dramatically during puberty; thus, in the 
child with delayed puberty and low growth velocity the IGF-I concentration for age may appear 
low, although the bone age-adjusted and puberty stage-adjusted IGF-I concentration would be 
normal. 
IGFBP-3 concentrations were thought to be potentially superior to measurement of IGF-I alone as 
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IGFBP-3 is less nutritionally sensitive than IGF-I. Multiple studies have, however, found no 
difference in IGFBP-3 concentrations between GHD and non-GHD subjects (16), with a poor 
sensitivity at 50% and no advantage over measurement of IGF-I alone (17). 
Neuroimaging 
The presence of an abnormality within the hypothalamo-pituitary axis provides powerful 
supporting evidence for a diagnosis of GHD. The most common radiological finding in GHD 
children is a variable combination of an ectopic posterior pituitary gland, anterior pituitary 
hypoplasia and a thin or interrupted pituitary stalk (18). Other abnormalities associated with GHD 
include hypothalamo-pituitary axis tumors such as craniopharyngioma, septo-optic dysplasia, 
corpus callosum hypoplasia/ agenesis, holoprosencephaly, thickened pituitary stalk (seen in 
Langerhans cell histiocytosis and germinoma) and the presence of an empty sella. 
Genetic investigations 
Mutations in GH1, GHRHR and RNPC3 genes have been identified in patients with isolated 
GHD, which may be associated with a normal MRI scan (19). The identification of a genetic 
mutation is particularly useful in supporting the diagnosis in cases of isolated GHD with a normal 
pituitary MRI. There are many other genes associated with GHD along with other pituitary 
deficiencies (POU1F1, PROP1, LHX3, LHX4, HESX1, OTX2, SOX2, SOX3, GLI2, GLI3, 
FGFR1, FGF8 and PROKR2) which are associated with additional clinical and radiological 
features.  
However, in only few patients with congenital MPHD it is possible to detect a causative gene 
mutation. Therefore, it is fundamental to define some criteria for selecting the patients who should 
undergo genetic analyses, such as the overall evaluation of hormonal clinical and 
neuroradiological phenotype (20). 
With the increasing clinical availability of genetic technologies such as whole exome and whole 
genome sequencing, screening for mutations to provide confirmation of the diagnosis of GHD is 
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likely to increase. 
Conclusions and Recommendations 
GHD remains a diagnosis principally based on medical history, clinical features and auxology 
supported by biochemical and neuroradiological studies.  
Problems continue to exist with GH and IGF-I assays for standardization, reproducibility and 
interassay variability. There are also problems with variability and reproducibility of the 
pharmacological stimulation tests. The most recent data on the selection of an optimal peak GH 
concentration come from Wagner et al (5) and could induce the Italian Medicine Agency to 
further reduce the cut-offs for peak GH levels on the stimulation tests to 7 mg/L. 
Pituitary MRI is required in all the confirmed patients with GHD. 
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